BioCentury
ARTICLE | Finance

BeiGene going global

Why cancer play BeiGene raised second-largest ever Chinese venture round

May 18, 2015 7:00 AM UTC

BeiGene Co. Ltd.'s existing and new investors have ponied up the second largest ever venture round for a Chinese biotech, as the company looks to globalize its clinical development and ramp up spending on a preclinical cancer asset that could become the cornerstone of its pipeline.

The RMB600 million ($96.6 million) infusion comes only about half a year after BeiGene raised $73.5 million in a series A round. That round previously held the second-place spot for Chinese venture rounds, trailing only Innovent Biologics Inc.'s $100 million series C round from January...